VRTX · News · 20260819N

Competition and Market Position

VERTEX PHARMACEUTICALS INC / MA · 2026-08-19 · Importance 31 · Surprise 42

A rival’s cystic-fibrosis clinical trial failed, reducing a near-term competitive threat to Vertex’s core cystic-fibrosis franchise. The report characterized Vertex as maintaining market leadership in cystic fibrosis and cited strategic diversification as an additional support for its outlook. The competitor and trial phase were not identified in the third-party report, so the precise commercial impact cannot be quantified.

Key facts

• Vertex Pharmaceuticals' market capitalization was reported at approximately $138 billion (approx. $138.62 billion in one mention). source
• Vertex Pharmaceuticals' stock returned 38.31% over the past year and 16.5% year-to-date (as reported with the $546.17 high). source
• Danske Bank A S purchased 158,064 shares of Vertex Pharmaceuticals valued at approximately $78.52 million during the second quarter, representing about 0.06% ownership. source
• Multiple institutional investors (examples: BlackRock Inc. and Norges Bank) significantly increased their stakes in Vertex, contributing to institutional ownership of 90.96%. source
• Wealthfront Advisers LLC purchased 41,608 shares of Vertex Pharmaceuticals during the second quarter valued at approximately $20.67 million. source
• Danica Pension Livsforsikringsaktieselskab purchased 27,829 shares of Vertex Pharmaceuticals for approximately $13.823 million during the second quarter. source
• TradingKey reported Vertex's market leadership in cystic fibrosis and noted strategic diversification efforts as contributors to bullish analyst ratings and increased institutional buying. source
• Vertex Pharmaceuticals' stock rose 4.52% to $552.06 on a strong trading day, marking the third consecutive day of gains. source